Paul Urquhart Cameron

Paul Urquhart Cameron

Auto-generated profile, based on publicly available information

Paul Urquhart Cameron

The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 1992 in Science
Verified
Journal Article
Closed access
PDF file
PCPaul U. Cameron
Paul U. Cameron
PFPeter S. Freudenthal
Peter S. Freudenthal
JBJeanne M. Barker
Jeanne M. Barker
SGStuart Gezelter
Stuart Gezelter
KIKayo Inaba
Kayo Inaba
RSRalph M. Steinman
Ralph M. Steinman
The paucity of virus-laden CD4 + cells in individuals infected with human immunodeficiency virus type-1 (HIV-1) contrasts with the greatly reduced numbers and function of these lymphocytes. A pathway is described whereby dendritic cells carry HIV-1 to uninfected T cells, amplifying the cytopathic effects of small amounts of virus. After exposure to HIV-1, dendritic cells continue to present superantigens and antigens, forming clusters with T cells that are driven to replicate. Infection of the dendritic cells cannot be detected, but the clustered T cells form syncytia, release virions, and die. Carriage of HIV-1 by dendritic cells may facilitate the lysis and loss of antigen specific CD4 + T cells in acquired immunodeficiency syndrome.

13 November 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JEJulian H Elliott
Julian H Elliott
FWFiona Wightman
Fiona Wightman
ASAjantha Solomon
Ajantha Solomon
KGKhader Ghneim
Khader Ghneim
JAJeffrey Ahlers
Jeffrey Ahlers
Sharon LewinSharon Lewin
Sharon Lewin
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important in maintaining HIV latency and histone deacetylase inhibitors (HDACi) may reverse latency by activating HIV transcription from latently infected CD4+ T-cells. We performed a single arm, open label, proof-of-concept study in which vorinostat, a pan-HDACi, was administered 400 mg orally once daily for 14 days to 20 HIV-infected individuals on suppressive antiretroviral therapy (ART). The primary endpoint was change in cell associated unspliced (CA-US) HIV RNA in total CD4+ T-cells from blood at day 14. The study is registered at ClinicalTrials.gov (NCT01365065). Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations. CA-US HIV RNA in blood increased significantly in 18/20 patients (90%) with a median fold change from baseline to peak value of 7.4 (IQR 3.4, 9.1). CA-US RNA was significantly elevated 8 hours post drug and remained elevated 70 days after last dose. Significant early changes in expression of genes associated with chromatin remodeling and activation of HIV transcription correlated with the magnitude of increased CA-US HIV RNA. There were no statistically significant changes in plasma HIV RNA, concentration of HIV DNA, integrated DNA, inducible virus in CD4+ T-cells or markers of T-cell activation. Vorinostat induced a significant and sustained increase in HIV transcription from latency in the majority of HIV-infected patients. However, additional interventions will be needed to efficiently induce virus production and ultimately eliminate latently infected cells. ClinicalTrials.gov NCT01365065 The major barrier to curing HIV is the long term persistence of latently infected resting memory T-cells in HIV-infected patients on antiretroviral therapy (ART). One strategy being pursued to eliminate latently infected cells is to activate HIV production from latently infected cells with the aim of killing latently infected cells via virus induced cell death or stimulation of an HIV-specific immune response. Histone deacetylases (HDACs) are important in maintaining HIV latency. Vorinostat, an inhibitor of HDACs (HDACi) licensed for the treatment of some malignancies, has been shown in laboratory studies and a clinical study of selected individuals to disrupt HIV latency. We examined the ability of standard dose vorinostat given daily for 14 days to activate latent HIV infection in unselected HIV-infected individuals on ART. The study showed evidence of activation of latent HIV infection in 18/20 (90%) of individuals and was safe and generally well tolerated. There were significant early changes in host gene expression, which persisted during and after the period of vorinostat. No changes were seen in immune activation or number of latently infected cells. Vorinostat was able to activate latent HIV infection in most individuals. Additional interventions will be needed to eliminate latent HIV infection.

23 September 2002 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
Stuart TurvilleStuart Turville
Stuart Turville
PCPaul U. Cameron
Paul U. Cameron
AHAmanda Handley
Amanda Handley
GLGeorge Lin
George Lin
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham

1 August 1994 in Cell
Verified
Journal Article
Closed access
MPM. Pope
M. Pope
MBMichiel GH Betjes
Michiel GH Betjes
NRN. Romani
N. Romani
HHH. Hirmand
H. Hirmand
PCP.U. Cameron
P.U. Cameron
RSR.M. Steinman
R.M. Steinman

15 March 2004 in Blood
Verified
Journal Article
Closed access
PDF file
Stuart TurvilleStuart Turville
Stuart Turville
JSJohn J. Santos
John J. Santos
IFInes Frank
Ines Frank
PCPaul U. Cameron
Paul U. Cameron
JWJohn Wilkinson
John Wilkinson
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham
HIV-1 subverts antigen processing in dendritic cells (DCs) resulting in viral uptake, infection, and transfer to T cells. Although DCs bound monomeric gp120 and HIV-1 similarly, virus rarely colocalized with endolysosomal markers, unlike gp120, suggesting HIV-1 alters endolysosomal trafficking. Virus within DC intracellular compartments rapidly moved to DC-CD4+ lymphocyte synapses when introduced to CD4+ lymphocyte cultures. Although viral harboring and transfer from nonlysosomal compartments was transient, given DC-associated virus protein, nucleic acids, and infectious HIV-1 transfer to CD4+, lymphocytes decayed within 24 hours. However a second long-term transfer phase was apparent in immature DCs after 48 hours as a zidovudine-sensitive rise in proviral DNA. Therefore, DCs transfer HIV-1 to CD4+ lymphocytes in 2 distinct phases. Immature and mature DCs first divert virus from the endolysosomal pathway to the DC–T-cell synapse. Secondly, the later transfer phase from immature DCs is through de novo HIV-1 production. Thus, the controversy of DCs being infected or not infected for the mechanics of viral transfer to CD4+ lymphocytes can be addressed as a function of time.

15 May 2007 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PEPhilip J. Ellery
Philip J. Ellery
ETEmma Tippett
Emma Tippett
YCYa-Lin Chiu
Ya-Lin Chiu
GPGeza Paukovics
Geza Paukovics
PCPaul U. Cameron
Paul U. Cameron
SCSuzanne M. Crowe
Suzanne M. Crowe
HIV-1 persists in peripheral blood monocytes in individuals receiving highly active antiretroviral therapy (HAART) with viral suppression, despite these cells being poorly susceptible to infection in vitro. Because very few monocytes harbor HIV-1 in vivo, we considered whether a subset of monocytes might be more permissive to infection. We show that a minor CD16+ monocyte subset preferentially harbors HIV-1 in infected individuals on HAART when compared with the majority of monocytes (CD14highCD16−). We confirmed this by in vitro experiments showing that CD16+ monocytes were more susceptible to CCR5-using strains of HIV-1, a finding that is associated with higher CCR5 expression on these cells. CD16+ monocytes were also more permissive to infection with a vesicular stomatitis virus G protein-pseudotyped reporter strain of HIV-1 than the majority of monocytes, suggesting that they are better able to support HIV-1 replication after entry. Consistent with this observation, high molecular mass complexes of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) were observed in CD16+ monocytes that were similar to those observed in highly permissive T cells. In contrast, CD14highCD16− monocytes contained low molecular mass active APOBEC3G, suggesting this is a mechanism of resistance to HIV-1 infection in these cells. Collectively, these data show that CD16+ monocytes are preferentially susceptible to HIV-1 entry, more permissive for replication, and constitute a continuing source of viral persistence during HAART.